Tandem Diabetes Care, Inc. (TNDM) - Get Report, a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders ("Annual Meeting") will be held in a virtual-only format due to continued public health concerns relating to COVID-19 and to prioritize the health and well-being of meeting participants. There is no change to the previously announced date and time of the meeting, which will be held on May 27, 2020 at 3:00pm Pacific Daylight Time.
Stockholders at the close of business on the record date, March 31, 2020, are entitled to participate in the Annual Meeting. To be admitted to the Annual Meeting at https://web.lumiagm.com/235916184, stockholders must enter the password "tandem2020" and the control number previously received on their proxy card. Once admitted to the Annual Meeting, stockholders who entered with a control number will be able to ask questions and vote during the Annual Meeting by following the instructions on the Annual Meeting website. Persons without a control number may enter the meeting as a guest, but may not ask questions or vote.
Stockholders who are "beneficial owners" and hold their shares through a broker, bank or other agent and who want to participate and vote at the virtual Annual Meeting, must obtain a valid legal proxy from their broker, bank or other agent and then register in advance to attend the Annual Meeting through our transfer agent, American Stock Transfer & Trust Company LLC, no later than 5:00 p.m. Eastern Time, on May 22, 2020. Directions for registering and voting can be found in the Notice of Change in Location of the 2020 Annual Meeting of Stockholders and other proxy materials filed with the U.S. Securities Exchange Commission and also posted to the Company's website at www.tandemdiabetes.com by clicking on "Investor Center" and then "Stockholder Meetings."
Whether or not stockholders plan to attend the virtual-only Annual Meeting, Tandem Diabetes Care encourages all stockholders to vote and submit their proxies in advance of the Annual Meeting by one of the methods described in the proxy materials previously provided.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005711/en/